Clovis Oncology Inc., the developer of cancer treatments that was considering a sale, hasn’t received any interest from buyers, said a person with knowledge of the matter.
The company, which was working with Credit Suisse Group AG and JPMorgan Chase & Co. to explore its options, contacted some potential suitors, though no sale negotiations took place, the person said, asking not to be identified as the information is private. Boulder, Colorado-based Clovis is no longer soliciting bids and is considering its alternatives, the person said.
